BACK

EMA finding a possible link between the Janssen COVID-19 vaccine and very rare cases of unusual blood clots with low blood platelets

This article was published on
April 20, 2021

This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.

The European Medicines Agency (EMA) has published a press release stating it finds a possible link between the Janssen COVID-19 vaccine and very rare cases of unusual blood clots with low blood platelets, but confirms that overall benefit-risk remains positive.

The European Medicines Agency (EMA) has published a press release stating it finds a possible link between the Janssen COVID-19 vaccine and very rare cases of unusual blood clots with low blood platelets, but confirms that overall benefit-risk remains positive.

Publication

What our experts say

Context and background

Resources

Media briefing

Media Release

Expert Comments: 

Prof Jonathan Ball

These side effects are very similar to those reported for Astra Zeneca COVID-19 vaccines, which does suggest that it is the inactivated Adenovirus delivery system that might be causing the problems.  It’s important to remember though, that in most people the benefits of these vaccines far outweigh the risks – these are incredibly rare potential side-effects.

Q&A

No items found.